SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 24.47 |
| Enterprise Value ($M) | 21.09 |
| Book Value ($M) | 2.58 |
| Book Value / Share | 0.11 |
| Price / Book | 9.47 |
| NCAV ($M) | 2.41 |
| NCAV / Share | 0.10 |
| Price / NCAV | 10.15 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -3.82 |
| Return on Assets (ROA) | -3.21 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.84 |
| Current Ratio | 2.21 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 4.40 |
| Assets | 4.58 |
| Liabilities | 1.99 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -9.90 |
| Net Income | -10.21 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -10.13 |
| Cash from Investing | 0.00 |
| Cash from Financing | 10.91 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Rimon Gold Assets Ltd | 9.99 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 15,450 | 88,472 | 17.46 | |
| 38,943 | 133,745 | 29.12 | |
| 21,903 | 77,615 | 28.22 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| NERV – Minerva Neurosciences, Inc. | NKTR – Nektar Therapeutics |
| NLSP – NLS Pharmaceutics AG | NRXP – NRx Pharmaceuticals, Inc. |
| NVCT – Nuvectis Pharma, Inc. |
Financial data and stock pages provided by
Fintel.io